How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,371 results for

ADHD Resources

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Attention deficit hyperactivity disorder: diagnosis and management

this guideline into practice 51 Context 53 More information 54 Update information 55 Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 62This guideline replaces CG72 and TA98. This guideline is the basis of QS39. Ov Overview erview This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children (...) , young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD. Who is it for? Healthcare professionals Commissioners and providers People with ADHD, and their families and carers Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 62Recommendations Recommendations People

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Guanfacine (Intuniv) for attention deficit hyperactivity disorder Full Text available with Trip Pro

-based information for Australian health professionals and consumers. Featured resources 2 October 2019 2 October 2019 26 September 2019 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Guanfacine (Intuniv) for attention deficit hyperactivity disorder New non-stimulant medicine (...) a suboptimal response to stimulants. PBS listing Authority Required (Streamlined) On 1 March 2019, guanfacine (Intuniv) was listed on the PBS as an Authority Required (Streamlined) listing. It was listed as an adjunctive treatment to stimulant medicines in patients with attention deficit hyperactivity disorder (ADHD). , To receive subsidised treatment, patients must have residual moderate to severe symptoms despite receiving a maximum tolerated dose (MTD) of dexamfetamine, methylphenidate

2019 National Prescribing Service Limited (Australia)

3. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents

, Ph.D. AHRQ Publication No. 18-EHC005-EF January 2018 ii Key Messages Purpose of Review To update a previous review by comparing strategies to diagnose, treat, and monitor children and adolescents with attention deficit hyperactivity disorder (ADHD). Key Messages • Evidence was insufficient on imaging or electroencephalogram to diagnose ADHD in children 7–17 years of age. • Little evidence adds to the 2011 report that found that methylphenidate is effective for children under age 6 with ADHD (...) . Harvard TH Chan School of Public Health Boston, MA Peter Jensen, M.D. Mayo Clinic Rochester, MN viii Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents Structured Abstract Objectives. Attention deficit hyperactivity disorder (ADHD) is a common pediatric neurobehavioral disorder often treated in the primary care setting. This systematic review updates and extends two previous Agency for Healthcare Research and Quality (AHRQ) systematic evidence reviews

2018 Effective Health Care Program (AHRQ)

4. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

in March 2016. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Guanfacine prolonged-release (Intuniv) is a non-stimulant treatment for children and young people with attention deficit hyperactivity disorder (ADHD). In 3 short-term, randomised controlled trials (RCTs) it was more effective than placebo at improving ADHD symptoms, although a beneficial effect on social functioning (...) February 2016). Atomoxetine 4 mg/ml oral solution (Strattera) costs £23.33–£233.33 for 28 days treatment at a dose of 10–100 mg daily (excluding VAT; Drug T ariff, February 2016). Introduction and current guidance Attention deficit hyperactivity disorder (ADHD) is a heterogeneous behavioural syndrome characterised by the core symptoms of hyperactivity, impulsivity and inattention. The NICE guideline on ADHD (currently being updated, publication expected January 2018) covers diagnosing and managing ADHD

2016 National Institute for Health and Clinical Excellence - Advice

5. Outpatient rehabilitation resources and medical expenditure in children with attention-deficit hyperactivity disorder in Taiwan. Full Text available with Trip Pro

Outpatient rehabilitation resources and medical expenditure in children with attention-deficit hyperactivity disorder in Taiwan. Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder in children. This study investigated the use of rehabilitation treatment in Taiwan. We selected children aged 3-12 years from the National Health Insurance Research Database from 2008 to 2012 and included them in the analysis. The children who received a diagnosis according (...) to the International Classification of Diseases, Ninth Revision, Clinical Modification were divided into two groups: ADHD and non-ADHD. We used the chi-squared test, independent sample t test, and multiple regression analysis to conduct the analysis. The utilisation of rehabilitation resources was higher in the ADHD group than in the non-ADHD group. The number of school-aged children with ADHD was higher than the number of preschool-aged children (p < 0.001). The highest utilisation of rehabilitation resources

2018 PLoS ONE

6. Seven steps to mapping health service provision: lessons learned from mapping services for adults with Attention-Deficit/Hyperactivity Disorder (ADHD) in the UK. Full Text available with Trip Pro

Seven steps to mapping health service provision: lessons learned from mapping services for adults with Attention-Deficit/Hyperactivity Disorder (ADHD) in the UK. ADHD affects some individuals throughout their lifespan, yet service provision for adults in the United Kingdom (UK) is patchy. Current methods for mapping health service provision are resource intensive, do not map specialist ADHD teams separately from generic mental health services, and often fail to triangulate government data (...) with accounts from service users and clinicians. Without a national audit that maps adult ADHD provision, it is difficult to quantify current gaps in provision and make the case for change. This paper describes the development of a seven step approach to map adult ADHD service provision in the UK.A mapping method was piloted in 2016 and run definitively in 2018. A seven step method was developed: 1. Defining the target service 2. Identifying key informants 3. Designing the survey 4. Data collection 5. Data

2019 BMC health services research

7. High Dose Stimulants for Attention Deficit Hyperactivity Disorder

and pharmacological treatment in social settings for children with ADHD. J Abnorm Child Psychol. 2014 Aug;42(6):1019-31. PubMed: PM24429997 Clinical Practice Guidelines – Uncertain Methodology 11. Canadian ADHD practice guidelines (CAP-guidelines) [Internet]. Markham (ON): Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA)]. 2011 [cited 2015 Jan 29]. Available from: http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf See: Supporting Document 7A, pages 7.11 – 7.16 Supporting Document (...) Hyperactivity Disorder: Clinical Effectiveness, Safety, and Guidelines DATE: 29 January 2015 RESEARCH QUESTIONS 1. What is the effectiveness and safety of high dose stimulants in children and adolescents (six to18 years) with attention deficit hyperactivity disorder (ADHD)? 2. What is the comparative effectiveness and safety of high dose stimulants in adults (>18 years) with ADHD? 3. What are the evidence-based guidelines regarding the use of high dose stimulants in patients with ADHD? KEY FINDINGS One

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder

Posted: May 24, 2018 Last Verified: May 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior (...) additive effects in improving attention in adults. However, the specific actions of these substances have not been examined in children and adolescents with attention deficit hyperactivity disorder (ADHD), who are characterized by impaired attention, hyperkinesia and impulsivity. Therefore, the investigators plan to study the functional activity of brains (both at rest and when performing standard tasks designed to measure attention) in children diagnosed with ADHD using functional magnetic resonance

2018 Clinical Trials

9. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. Full Text available with Trip Pro

Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. Objective: To assess treatment patterns, health care resource utilization, and health care costs associated with use of atypical antipsychotics (AAPs) or the nonstimulant guanfacine extended release (GXR) after stimulant therapy for attention-deficit (...) /hyperactivity disorder (ADHD). In Canada, GXR is approved as a monotherapy for children and adolescents with ADHD or as an adjunct to stimulants, and AAPs are commonly used off-label as an adjunct to stimulants. Methods: Health care claims data (January 1, 2007 to March 31, 2016) from Quebec's provincial health plan were assessed for individuals with ADHD, 6-17 years of age, who received ≥1 stimulant followed by a first AAP or GXR prescription (index medication), without a diagnosis for which AAPs

2019 Journal of Child and Adolescent Psychopharmacology

10. Co Morbid Attention Deficit and Hyperactivity Disorder(ADHD) and Developmental Co Ordination Disorder (DCD)

Product: No Keywords provided by Pam Dawson, University of KwaZulu: ADHD/ADD DCD Exercises Neurostimulant Drugs Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Motor Skills Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) : The Effects of Exercise Therapy on the Co-Morbidity of Attention Deficit and Hyperactivity Disorder (ADHD) and Developmental Co-Ordination Disorder. (DCD) Actual Study Start Date : May 2, 2018 Estimated Primary Completion Date : August 2018 Estimated Study Completion Date : December 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1. Neurostimulant pharmaceutical drugs.. 1.Participants receiving medicinal

2018 Clinical Trials

11. Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD)

magnetic resonance imaging (MRI) brain connectivity biomarker treatment response methylphenidate stimulant medication Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants (...) Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD) Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Brain Connectivity

2018 Clinical Trials

12. Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD)

a U.S. FDA-regulated Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: No Pediatric Postmarket Surveillance of a Device Product: No Keywords provided by University of Pennsylvania: ADHD TMS Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs (...) Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD) Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

13. Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Amphetamine Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents (...) Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

14. Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children

: Other Time Perspective: Prospective Official Title: Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children Actual Study Start Date : November 7, 2017 Estimated Primary Completion Date : November 2020 Estimated Study Completion Date : November 2020 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort Intervention/treatment ADHD Patient with ADHD diagnosis (...) terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders

2018 Clinical Trials

15. Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder - NICE CKS Share Attention deficit hyperactivity disorder: Summary Attention deficit hyperactivity disorder (ADHD) is a behavioural syndrome characterized by hyperactivity, impulsivity, and inattention. ADHD should be suspected if the core symptoms of hyperactivity, inattention, and/or impulsivity have been present since childhood. These core symptoms are age-inappropriate and result in significant psychological (...) to 60 years. This CKS topic is based on the National Institute for Health and Care Excellence guideline Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults [ ]. This CKS topic covers the diagnosis, assessment, and management in primary care of suspected attention deficit hyperactivity disorder (ADHD) in children, young people, and adults. This CKS topic does not cover in detail the diagnosis and management of ADHD by specialists

2018 NICE Clinical Knowledge Summaries

16. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine Full Text available with Trip Pro

Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine To describe the characteristics and medication treatment patterns of adult patients with attention-deficit/hyperactivity disorder (ADHD) prescribed atomoxetine in Japan.A retrospective analysis of insurance claims data was conducted using the Japan Medical Data Center database. Adults (≥18 years) with ADHD who had ≥1 atomoxetine claim from (...) % of patients were male. Nearly 72.0% of the patients had at least one comorbid mental health condition in the baseline period; depression (43.8%) and insomnia (40.7%) were the most common mental health comorbidities. Most common physical comorbidities were chronic obstructive pulmonary disease (14.4%) and diabetes (12.9%). Non-ADHD-specific psychotropics were prescribed to 59.7% of patients during the baseline period and to 65.9% during the follow-up period; 6.6% were prescribed non-ADHD-specific

2018 Neuropsychiatric disease and treatment

17. Guideline Development for Technological Interventions for Children and Young People to Self-Manage Attention Deficit Hyperactivity Disorder: Realist Evaluation. Full Text available with Trip Pro

Guideline Development for Technological Interventions for Children and Young People to Self-Manage Attention Deficit Hyperactivity Disorder: Realist Evaluation. Attention deficit hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. ADHD can affect the individual, the individual's family, and the community. ADHD is managed using pharmacological and nonpharmacological treatments, which principally involves others (...) -range theories of behavior change to underpin the propositions. Phase 3 involved the identification and development of context mechanism outcome configurations (CMOCs), which essentially state which elements of the intervention could be affected by which contexts and what the outcome of these could be. Phase 4 involved the validation and refinement of the propositions from phase 1 via interviews with key stakeholders (CAYP with ADHD, their parents and specialist clinicians). Phase 5 involved using

2019 Journal of medical Internet research

18. Resumption of attention-deficit hyperactivity disorder medication in early adulthood: findings from a UK primary care prescribing study. Full Text available with Trip Pro

Resumption of attention-deficit hyperactivity disorder medication in early adulthood: findings from a UK primary care prescribing study. This study aimed to examine the resumption of attention-deficit hyperactivity disorder (ADHD) prescriptions in early adulthood in young people whose ADHD prescriptions stopped in adolescence. Whilst prescribing studies indicate that the proportion of those with ADHD stopping treatment in late adolescence remains in excess of the proportion expected (...) to be symptom free, very few studies have examined patterns of resumption amongst young adults previously prescribed medication. Primary care records from the UK Clinical Practice Research Datalink from 2008 to 2013 were used to examine the outcome of resumption of ADHD prescriptions from age 20 years in a sample of cases with ADHD whose prescriptions stopped aged 14-18 years. A Cox regression model was fitted to explore variables that could theoretically be associated with resumption of prescriptions

2019 European child & adolescent psychiatry

19. Health-related quality of life and peer relationships in adolescents with developmental coordination disorder and attention-deficit-hyperactivity disorder. Full Text available with Trip Pro

Health-related quality of life and peer relationships in adolescents with developmental coordination disorder and attention-deficit-hyperactivity disorder. Health-related quality of life (HRQoL) and peer relationships were investigated in adolescents with developmental coordination disorder (DCD) and attention-deficit-hyperactivity disorder (ADHD).Adolescents with DCD (n=9), ADHD (n=9), DCD and ADHD (n=10), and typically developing adolescents (n=16) completed the following questionnaires (...) -related quality of life (HRQoL) versus typically developing controls. Having DCD and attention-deficit-hyperactivity disorder (ADHD) was associated with poorer HRQoL. Adolescents with DCD and ADHD experience significantly higher levels of peer victimization than typically developing adolescents. HRQoL and peer relationships are significantly associated in adolescent respondents.© 2018 Mac Keith Press.

2018 Developmental Medicine and Child Neurology

20. Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence

age 43) (cross-over study) Randomized, double- blind, placebo- controlled, cross-over study 6 weeks Improvement in ADHD symptoms measured by the DSM-IV ADHD Behavior Checklist for Adults, the Controlled Oral Word Association Test (COWAT), Stroop and Digit Span Safety (adverse effects) ADHD: attention-deficit/hyperactivity disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders (4 th edition) Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for ADHD 12 Appendix 3 (...) by the owners’ own terms and conditions. TITLE: Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence DATE: 21 March 2013 CONTEXT AND POLICY ISSUES Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder with inappropriate levels of inattention, hyperactivity, and impulsivity manifesting in childhood and continuing into adulthood, resulting in functional

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>